Core Insights - Daxing Biopharmaceutical Industry Base has achieved significant milestones, including being recognized as a national-level "Green Industrial Park" and a five-star national new-type industrialization demonstration base, with plans for expansion and development in the biopharmaceutical sector [1][2][8] Group 1: Development Milestones - In 2021, Daxing Biopharmaceutical Industry Base was approved for a 9.1 square kilometer expansion, marking its entry into the trillion-level industrial park category [1] - The base was awarded the title of "Green Industrial Park" in 2022 and has been recognized for its innovative development strategies [1][2] - The construction of the new campus for Capital Medical University commenced in 2023, enhancing the collaborative innovation framework of "medical education, research, and production" [1][8] Group 2: Expansion Projects - The first industrial land project in the southern expansion area, the Ande Medical Health Industry Park, broke ground in February 2025, with a total investment of approximately 300 million yuan [7] - The northern expansion area, covering 5.5 square kilometers, focuses on living and service facilities, with the new campus of Capital Medical University as a key project [8] - During the "14th Five-Year Plan" period, the base completed 12 transactions for industrial land, emphasizing high-standard planning before construction [8] Group 3: Industry Focus and Innovation - The base has established a "3+5" industrial development roadmap, focusing on traditional Chinese medicine, vaccines, and high-end medical devices, while also exploring emerging fields like cell and gene therapy [10][11] - Daxing has become a hub for vaccine production, housing leading companies in the sector, and has transitioned from "following innovation" to "original breakthroughs" [10] - The base is also strengthening its position in high-end medical devices, with advancements in surgical robots and innovative medical implants [11] Group 4: Service and Support for Enterprises - Daxing Biopharmaceutical Industry Base provides comprehensive services for enterprises, including project site selection, business registration, environmental assessments, and policy applications [14] - A one-stop service platform has been established, integrating government services and industry resources, which has facilitated over 26,000 services to enterprises [14] - The base has organized various events to enhance collaboration and visibility for enterprises, leading to successful international market expansions for over 20 companies [15] Group 5: Future Outlook - The base aims to further optimize its industrial system by focusing on the "3+2+N" model, which includes strengthening existing industries and exploring new potential sectors [17] - The "15th Five-Year Plan" emphasizes the development of new productive forces and high-quality economic growth, aligning with Daxing's strategic goals [17] - Daxing Biopharmaceutical Industry Base is committed to continuing its role as a key player in the biopharmaceutical industry, with plans for further expansion and innovation [17]

联馨药业在长期发展过程中，既继承了中药尊古、重视传统经验的传统精髓，也面临着向现代化、智能 化生产模式转型的时代要求。 费心懿/文 三是数字化转型经验缺乏。传统医药生产流程存在浪费和低效环节，在推进数字化转型过程中，内部专 业人才与专项团队配置有待完善，往往会一定程度影响转型举措的落地效率与预期目标的达成。 当前，数字化与低碳化转型浪潮正以不可逆之势席卷全球工业领域，成为驱动行业高质量发展的核心动 能。从政策引导到技术赋能，从企业实践到生态重构，这场变革正深度重塑传统行业的发展逻辑与竞争 格局。为此，联馨药业提出，在5年内完成生产设备、生产环境、工艺流程等传统生产线的全面升级， 为持续创新发展提供源源动力。 一、案例背景 随着政策的不断推进以及竞争格局的演变，医药行业的数智化转型成为推动产业升级、提升核心竞争 力、挖掘新增长机遇的关键力量。医药工业高质量发展是推进新型工业化和建设制造强国的重要任务， 是实施健康中国战略的重要支撑。 2025年4月，工信部、国家卫健委等七部门联合印发《医药工业数智化转型实施方案（2025-2030年）》 （下称《实施方案》）标志着国内医药工业正式迈入全产业链数智化转型的关键攻坚 ...